miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2

Qiu,Tianzhu; Zhou,Li; Wang,Tongshan; Xu,Jing; Wang,Jian; Chen,Wenjiao; Zhou,Xin; Huang,Zebo; Zhu,Wei; Shu,Yongqian; Liu,Ping

doi:10.3892/ijmm.2013.1439

miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2

Authors:
- Tianzhu Qiu
- Li Zhou
- Tongshan Wang
- Jing Xu
- Jian Wang
- Wenjiao Chen
- Xin Zhou
- Zebo Huang
- Wei Zhu
- Yongqian Shu
- Ping Liu
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: July 12, 2013 https://doi.org/10.3892/ijmm.2013.1439
Pages: 593-598

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance is one of the leading causes of chemotherapy failure in cancer treatment. MicroRNAs (miRNAs or miRs) are short non-coding RNA molecules that post-transcriptionally regulate gene expression and play a critical role in diverse biological processes. In this study, we report that miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin. The expression of miR-503 was decreased in the cisplatin-resistant non-small cell lung cancer cells, A549/CDDP, compared with the parental A549 cells. The overexpression of miR-503 sensitized the A549/CDDP cells to cisplatin, whereas the inhibition of miR-503 in the A549 cells increased resistance to cisplatin. Mechanistically, miR-503 specifically targeted Bcl-2, an anti-apoptotic protein upregulated in the A549/CDDP cells. The ectopic expression of miR-503 reduced the Bcl-2 protein level and sensitized the A549/CDDP cells to cisplatin-induced apoptosis. Taken together, our results suggest that miR-503 regulates cell apoptosis, at least in part by targeting Bcl-2, and thus modulates the resistance of non-small cell lung cancer cells to cisplatin.

View Figures

View References

1	Szakács G, Paterson JK, Ludwig JA, et al: Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 5:219–234. 2006.
2	Zhang K, Mack P and Wong KP: Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol. 12:871–882. 1998.PubMed/NCBI
3	Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
4	Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
5	Fojo T: Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat. 10:59–67. 2007. View Article : Google Scholar
6	Glasspool RM, Teodoridis JM and Brown R: Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer. 94:1087–1092. 2006. View Article : Google Scholar : PubMed/NCBI
7	Sharma SV, Lee DY, Li B, et al: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 141:69–80. 2010. View Article : Google Scholar : PubMed/NCBI
8	Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993.
9	Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
10	Chen GQ, Zhao ZW, Zhou HY, et al: Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med Oncol. 27:406–415. 2010. View Article : Google Scholar : PubMed/NCBI
11	Bourguignon LY, Spevak CC, Wong G, et al: Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem. 284:26533–26546. 2009.
12	Li Y, Li W, Yang Y, et al: MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res. 1286:13–18. 2009. View Article : Google Scholar : PubMed/NCBI
13	Xu K, Liang X, Cui D, et al: miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog. 52:70–78. 2013. View Article : Google Scholar : PubMed/NCBI
14	Xia L, Zhang D, Du R, et al: miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 123:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
15	Chen J, Tian W, Cai H, et al: Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol. 29:2527–2534. 2012. View Article : Google Scholar : PubMed/NCBI
16	Zhou J and Wang W: Analysis of microRNA expression profiling identifies microRNA-503 regulates metastatic function in hepatocellular cancer cell. J Surg Oncol. 104:278–283. 2011. View Article : Google Scholar : PubMed/NCBI
17	Lu YC, Chen YJ, Wang HM, et al: Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. Cancer Prev Res (Phila). 5:665–674. 2012. View Article : Google Scholar : PubMed/NCBI
18	Özata DM, Caramuta S, Velázquez-Fernández D, et al: The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer. 18:643–655. 2011.PubMed/NCBI
19	Corbetta S, Vaira V, Guarnieri V, et al: Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer. 17:135–146. 2010. View Article : Google Scholar
20	Zhao JJ, Yang J, Lin J, et al: Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst. 25:13–20. 2009. View Article : Google Scholar : PubMed/NCBI
21	Cui YH, Xiao L, Rao JN, et al: miR-503 represses CUG-binding protein 1 translation by recruiting CUGBP1 mRNA to processing bodies. Mol Biol Cell. 23:151–162. 2012. View Article : Google Scholar : PubMed/NCBI
22	Jiang Q, Feng MG and Mo YY: Systematic validation of predicted microRNAs for cyclin D1. BMC Cancer. 9:1942009. View Article : Google Scholar : PubMed/NCBI
23	Cheng G, Sun S, Wang Z and Jin S: Investigation of the interaction between the miR-503 and CD40 genes in irradiated U937 cells. Radiat Oncol. 7:382012. View Article : Google Scholar : PubMed/NCBI
24	Zhu W, Zhu D, Lu S, et al: miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 29:384–391. 2012. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Yamaue H, Tanimura H, Noguchi K, et al: Chemosensitivity testing of fresh human gastric cancer with highly purified tumor cells using the MTT assay. Br J Cancer. 66:794–799. 1992. View Article : Google Scholar : PubMed/NCBI
27	Yamaue H, Tani M, Onishi H, et al: Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas. 25:366–372. 2002. View Article : Google Scholar
28	Wang S, Yang D and Lippman ME: Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol. 30(Suppl 16): S133–S142. 2003. View Article : Google Scholar : PubMed/NCBI
29	Reed JC: Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Prac Oncol. 3:388–398. 2006. View Article : Google Scholar : PubMed/NCBI
30	Tanida S, Mizoshita T, Ozeki K, et al: Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int J Surg Oncol. 2012:8628792012.PubMed/NCBI
31	Beale PJ, Rogers P, Boxall F, et al: BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer. 82:436–440. 2000.PubMed/NCBI
32	Yu L and Wang Z: Difference in expression of Bcl-2 and Bcl-xl genes in cisplatin-sensitive and cisplatin-resistant human in ovarian cancer cell lines. J Huazhong Univ Sci Technolog Med Sci. 24:151–153. 2004. View Article : Google Scholar : PubMed/NCBI
33	Dong Z and Wang J: Hypoxia selection of death-resistant cells. A role for Bcl-X(L). J Biol Chem. 279:9215–9221. 2004. View Article : Google Scholar : PubMed/NCBI
34	Williams J, Lucas PC, Griffith KA, et al: Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol. 96:287–295. 2005. View Article : Google Scholar : PubMed/NCBI
35	Zhu W, Shan X, Wang TS, et al: miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
36	Baylin SB: DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2(Suppl 1): S4–S11. 2005. View Article : Google Scholar : PubMed/NCBI
37	Li D, Zhao Y, Liu C, et al: Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
38	Saito Y, Liang G, Egger G, et al: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 9:435–443. 2006. View Article : Google Scholar : PubMed/NCBI
39	Datta J, Kutay H, Nasser MW, et al: Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 68:5049–5058. 2008. View Article : Google Scholar : PubMed/NCBI